Format

Send to

Choose Destination
Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Author information

1
Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium clinicalguidelines@esmo.org.
2
Medical Oncology Department, INCLIVA University of Valencia, Valencia, Spain.
3
Hepato-Biliary Centre, Paul Brousse Hospital, Villejuif, France.
4
Medical Oncology, IRCCS San Martino Hospital, Genova, Italy.
5
Research Institute for Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
6
Division of Oncology, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.
7
Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.
8
School of Medicine, University of Turin, Turin, Italy.
9
Division of Hematology/Oncology, Northwestern Medical Group, Chicago, USA.
10
Department of Oncology, St László Hospital, Budapest, Hungary.
11
Division of Medical Oncology, Seconda Università di Napoli, Naples, Italy.
12
Abdominal Surgery, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.
13
Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain.
14
Medical Oncology, Institut de Cancérologie de l'Ouest (ICO), St Herblain.
15
Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
16
Department of Medical Oncology, University of Pisa, Pisa, Italy Division of Medical Oncology, Department of Oncology, University Hospital 'S. Chiara', Istituto Toscano Tumori, Pisa, Italy.
17
Division of Medical Oncology, Mayo Clinic, Rochester, USA.
18
Department of Surgery I, Rudolfstiftung Hospital, Vienna, Austria.
19
Department of Radiation Oncology, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium.
20
Comprehensive Cancer Center, University Clinic Munich, Munich, Germany.
21
Instituto do Câncer do Estado de São Paulo, University of São Paulo, São Paulo, Brazil.
22
Northwest German Cancer Center, University Campus Klinikum Oldenburg, Oldenburg, Germany.
23
Cancer Center, Ospedale Giovanni XXIII, Bergamo, Italy.
24
Digestive Oncology Department, European Hospital Georges Pompidou, Paris, France.
25
Department of Clinical Oncology, Prince of Wales Hospital, State Key Laboratory in Oncology in South China, Chinese University of Hong Kong, Shatin, Hong Kong.
26
CRUK/MRC Oxford Institute for Radiation Oncology, Gray Laboratories, University of Oxford, Oxford, UK.
27
Department of Clinical Oncology and Outpatient Treatment Center, Aichi Cancer Center Hospital, Nagoya, Japan.
28
Cell Biology and Biotherapy Unit, I.N.T. Fondazione G. Pascale, Napoli, Italy.
29
Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki, Finland Department of Oncology, University of Helsinki, Helsinki, Finland.
30
The Institute of Cancer Research and The Royal Marsden Hospital, London, UK.
31
Department of Medical Oncology, Bank of Cyprus Oncology Centre, Nicosia, Cyprus.
32
Department of Medical Oncology, University of Ioannina, Ioannina, Greece.
33
Department of Oncology, Odense University Hospital, Odense, Denmark.
34
Haematology and Medical Oncology Unit, Queen Elizabeth Hospital, Woodville, Australia.
35
Department of Medical Oncology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
36
Department of Radiology and Nuclear Medicine, University Clinic Magdeburg, Magdeburg, Germany.
37
Digestive Tumors Unit, Geneva University Hospitals (HUG), Geneva, Switzerland.
38
Catalan Institute of Oncology (ICO), Barcelona, Spain.
39
Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
40
Department of Internal Medicine IV, University Clinic Halle, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
41
Medical Oncology Department, Vall d' Hebron University Hospital, Vall d'Hebron Institute of Oncology (V.H.I.O.), Barcelona, Spain.
42
Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.
43
Department of Cancer Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
44
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
45
Instituto CUF de Oncologia (ICO), Lisbon, Portugal.

Abstract

Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

KEYWORDS:

ESMO; clinical practice guidelines; colorectal cancer; consensus

PMID:
27380959
DOI:
10.1093/annonc/mdw235
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center